PT  - JOURNAL ARTICLE
AU  - Jürgen Braun
AU  - Xenofon Baraliakos
AU  - Atul Deodhar
AU  - Dominique Baeten
AU  - Joachim Sieper
AU  - Paul Emery
AU  - Aimee Readie
AU  - Ruvie Martin
AU  - Shephard Mpofu
AU  - Hanno B Richards
TI  - Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
AID  - 10.1136/annrheumdis-2016-209730
DP  - 2017 Jun 01
TA  - Annals of the Rheumatic Diseases
PG  - 1070--1077
VI  - 76
IP  - 6
4099  - http://ard.bmj.com/content/76/6/1070.short
4100  - http://ard.bmj.com/content/76/6/1070.full
SO  - Ann Rheum Dis2017 Jun 01; 76
AB  - Objective To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS).Methods In the phase III MEASURE 1 study, patients were randomised to receive intravenous secukinumab 10 mg/kg (at baseline, week 2 and week 4) followed by subcutaneous secukinumab 150 mg (intravenous 150 mg; n=125) or 75 mg (intravenous 75 mg; n=124) every four weeks, or matched placebo (n=122). Placebo-treated patients were re-randomised to subcutaneous secukinumab 150 or 75 mg from week 16. Clinical efficacy assessments included Assessment of SpondyloArthritis international Society 20 (ASAS20) response rates through week 104. Radiographic changes at week 104 were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).Results 97 (77.6%) and 103 (83.1%) patients in the intravenous 150 mg and intravenous 75 mg groups, respectively, completed week 104. In the full analysis set (intent-to-treat), ASAS20 response rates at week 104 were 73.7% and 68.0% in the intravenous 150 mg and intravenous 75 mg groups, respectively. Among patients with evaluable X-rays who were originally randomised to secukinumab (n=168), mean change in mSASSS from baseline to week 104 was 0.30±2.53. Serious adverse events were reported in 12.2% and 13.4% of patients in the 150 mg and 75 mg groups, respectively.Conclusions Secukinumab improved AS signs and symptoms through 2 years of therapy, with no unexpected safety findings. Data from this study suggest a low mean progression of spinal radiographic changes, which will need to be confirmed in longer-term controlled studies.Trial registration number NCT01358175.